Last reviewed · How we verify

Migraine — Treatment Landscape & Competitive Intelligence

Migraine (Neurology) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Neurology 10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Migraine, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Vyepti EPTINEZUMAB Lundbeck Seattle BioPharmaceuticals, Inc. Calcitonin Gene-related Peptide Antagonist [EPC] Calcitonin gene-related peptide 1 2020-01-01
Nurtec Odt rimegepant Pfizer Calcitonin Gene-related Peptide Receptor Antagonist calcitonin gene-related peptide receptor 2020-01-01
Nurtec Odt Rimegepant Sulfate Pfizer CGRP receptor antagonist Calcitonin gene-related peptide (CGRP) receptor 2020-01-01
Reyvow LASMIDITAN Eli Lilly 5-hydroxytryptamine receptor 1F 2019-01-01
Ubrelvy UBROGEPANT AbbVie Calcitonin Gene-related Peptide Receptor Antagonist [EPC] Calcitonin gene-related peptide type 1 receptor 2019-01-01
Aimovig ERENUMAB Amgen Calcitonin-gene-related peptide receptor 2018-01-01
Emgality GALCANEZUMAB Eli Lilly Calcitonin gene-related peptide 1 2018-01-01
Ajovy FREMANEZUMAB Teva Calcitonin gene-related peptide 1 2018-01-01
Relpax ELETRIPTAN Upjohn Serotonin-1b and Serotonin-1d Receptor Agonist 5-hydroxytryptamine receptor 1D 2002-01-01
Axert ALMOTRIPTAN Johnson & Johnson Serotonin-1b and Serotonin-1d Receptor Agonist 5-hydroxytryptamine receptor 1B 2001-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 3 drugs in Migraine
  2. · 3 drugs in Migraine
  3. Eli Lilly · 2 drugs in Migraine
  4. Lundbeck Seattle BioPharmaceuticals, Inc. · 2 drugs in Migraine
  5. GSK · 2 drugs in Migraine
  6. Endo · 1 drug in Migraine
  7. Endo Operations · 1 drug in Migraine
  8. Generic (originally Syntex) · 1 drug in Migraine
  9. Gensco · 1 drug in Migraine
  10. Hikma · 1 drug in Migraine
  11. Institute of Child Health · 1 drug in Migraine
  12. Johnson & Johnson · 1 drug in Migraine

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Migraine:

Cite this brief

Drug Landscape (2026). Migraine — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/migraine. Accessed 2026-05-13.

Related